Company news
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) news
Xenon Pharmaceuticals Inc. news releases on 6ix. Latest, Aug 12, 2024: Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
Press releases — page 2
Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
August 11, 2024
Xenon to Report Q2 2024 Financial Results on August 8, 2024
July 31, 2024
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 4, 2024
Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
May 27, 2024
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 8, 2024
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
May 7, 2024
Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
May 6, 2024
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
May 1, 2024
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
April 15, 2024
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 9, 2024
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 3, 2024
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
March 11, 2024
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
March 4, 2024
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 28, 2024
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
February 21, 2024
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
January 7, 2024
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 2, 2024
Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
December 3, 2023
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
December 1, 2023
Xenon Pharmaceuticals Announces Proposed Public Offering
November 28, 2023
Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
November 28, 2023
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)
November 26, 2023
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
November 8, 2023
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 7, 2023
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update
October 31, 2023
Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology
October 8, 2023
Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
October 5, 2023
Xenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
September 13, 2023
Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder
September 11, 2023
Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress
September 3, 2023
Xenon Pharmaceuticals to Present at the Wells Fargo 2023 Healthcare Conference
August 30, 2023
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 8, 2023
Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover
August 7, 2023
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Corporate Update
August 1, 2023
Xenon Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 5, 2023
Xenon Pharmaceuticals to Present at the 2023 Jefferies Healthcare Conference
May 30, 2023
Xenon Pharmaceuticals to Present at the 2023 RBC Capital Markets Global Healthcare Conference
May 10, 2023
Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 8, 2023
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2023
May 2, 2023
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Corporate Update
May 1, 2023
Xenon Pharmaceuticals Showcases Its XEN1101 Epilepsy Program at the 2023 American Academy of Neurology (AAN) Annual Meeting
April 23, 2023
Xenon Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
April 20, 2023
Xenon Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 17, 2023
Xenon Pharmaceuticals to Present at the Stifel 2023 CNS Days
March 21, 2023
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 28, 2023
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
February 21, 2023
Xenon Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
February 7, 2023
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023
January 8, 2023
Xenon Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 3, 2023
Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)
December 1, 2022